Advertisement

American Journal of Clinical Dermatology

, Volume 20, Issue 3, pp 325–333 | Cite as

Neutrophilic Dermatoses Associated with Myeloid Malignancies

  • Clémence LepelletierEmail author
  • Jean-David Bouaziz
  • Michel Rybojad
  • Martine Bagot
  • Sophie Georgin-Lavialle
  • Marie-Dominique Vignon-Pennamen
Leading Article

Abstract

Neutrophilic dermatoses (ND) are a group of conditions characterized by an aseptic accumulation of polymorphonuclear leukocytes in the skin. Occurrence of ND in association with myeloid malignancies, mainly myelodysplastic syndrome and myelogenous acute leukemia, is not rare and is often associated with a poor prognosis. Recent findings have improved understanding of the pathophysiology of myeloid malignancy-associated ND. We review the clinical spectrum of myeloid malignancy-associated ND with an emphasis on recently identified mechanisms. Myeloid leukemia cells retain the potential for terminal differentiation into polymorphonuclear leukocytes in the skin. Many studies suggest a clonal link between myeloid malignancies and ND. Activation of autoinflammatory pathways (NOD-like receptor family pyrin domain-containing-3, Familial Mediterranean Fever Gene) in the clonal cells of myeloid disorders may also be involved in this setting.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of interest

CL, J-DB, MR MB, SG-L, and M-DV-P have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Korn C, Mendez-Ferrer S. Myeloid malignancies and the microenvironment. Blood. 2017;129(7):811–22.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.CrossRefPubMedGoogle Scholar
  3. 3.
    Wallach D, Vignon-Pennamen MD. From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. J Am Acad Dermatol. 2006;55:1066–71.CrossRefPubMedGoogle Scholar
  4. 4.
    Maalouf D, Battistella M, Bouaziz J-D. Neutrophilic dermatosis: disease mechanism and treatment. Curr Opin Hematol. 2015;22:23–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Cohen PR. Sweet’s syndrome—a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2(1):34.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ghoufi L, Ortonne N, Ingen-Housz-Oro S, et al. Histiocytoid sweet syndrome is more frequently associated with myelodysplastic syndromes than the classical neutrophilic variant: a comparative series of 62 patients. Medicine (Baltimore). 2016;95(15):e3033.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rochet NM, Chavan RN, Cappel MA, et al. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol. 2013;69(4):557–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Nelson CA, Noe MH, Mc Mahon CN, et al. Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol. 2018;78(2):303–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Kazmi SM, Pemmaraju N, Patel KP, et al. Characteristics of sweet syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(6):358–63.CrossRefPubMedGoogle Scholar
  10. 10.
    El-Khalawany M, Aboeldahab S, Mosbeh AS, Thabet A. Clinicopathologic, immunophenotyping and cytogenetic analysis of Sweet syndrome in Egyptian patients with acute myeloid leukemia. Pathol Res Pract. 2017;213(2):143–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Marcoval J, Martín-Callizo C, Valentí-Medina F, Bonfill-Ortí M, Martínez-Molina L. Sweet syndrome: long-term follow-up of 138 patients. Clin Exp Dermatol. 2016;41(7):741–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Amouri M, Masmoudi A, Ammar M, et al. Sweet’s syndrome: a retrospective study of 90 cases from a tertiary care center. Int J Dermatol. 2016;55(9):1033 (PubMed-9).CrossRefPubMedGoogle Scholar
  13. 13.
    Chan MP, Duncan LM, Nazarian RM. Subcutaneous Sweet syndrome in the setting of myeloid disorders: a case series and review of the literature. J Am Acad Dermatol. 2013;68(6):1006–15.CrossRefPubMedGoogle Scholar
  14. 14.
    Neoh CY, Tan AW, Ng SK. Sweet’s syndrome: a spectrum of unusual clinical presentations and associations. Br J Dermatol. 2007;156(3):480–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Li Y, Ai M, Yang WB, et al. Vital organ involvement in Sweet’s syndrome with myelodysplastic syndrome: a case report and literature review. Int J Dermatol. 2015;54(11):1303–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Bourke JF, Keohane S, Long CC, et al. Sweet’s syndrome and malignancy in the UK. Br J Dermatol. 1997;137(4):609–13.CrossRefPubMedGoogle Scholar
  17. 17.
    Casarin Costa JR, Virgens AR, Mestre LO, et al. Sweet Syndrome. J Cutan Med Surg. 2017;21(3):211–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Requena L, Kutzner H, Palmedo G, et al. Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol. 2005;141(7):834–42.CrossRefPubMedGoogle Scholar
  19. 19.
    So JK, Carlos CA, Frucht CS, Cohen PR. Histiocytoid giant cellulitis-like Sweet’s syndrome: case report and review of the literature. Dermatol Online J. 2015;21(3):13030/qt0682f5wp.PubMedGoogle Scholar
  20. 20.
    Chavan RN, Cappel MA, Ketterling RP, et al. Histiocytoid Sweet syndrome may indicate leukemia cutis: a novel application of fluorescence in situ hybridization. J Am Acad Dermatol. 2014;70(6):1021–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Magro CM, Momtahen S, Nguyen GH, et al. Histiocytoid Sweet’s Syndrome: a localized cutaneous proliferation of macrophages frequently associated with chronic myeloproliferative disease. Eur J Dermatol. 2015;25(4):335–41.PubMedGoogle Scholar
  22. 22.
    Vignon-Pennamen MD, Juillard C, Rybojad M, et al. Chronic recurrent lymphocytic Sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases. Arch Dermatol. 2006;142:1170–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Alegría-Landa V, Rodríguez-Pinilla SM, Santos-Briz A, et al. Clinicopathologic, immunohistochemical, and molecular features of histiocytoid Sweet syndrome. JAMA Dermatol. 2017;153(7):651–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Anzalone CL, Cohen PR. Acute febrile neutrophilic dermatosis (Sweet’s syndrome). Curr Opin Hematol. 2013;20(1):26–35.CrossRefPubMedGoogle Scholar
  25. 25.
    Cohen PR. Skin lesions of Sweet syndrome and its dorsal hand variant contain vasculitis: an oxymoron or an epiphenomenon? Arch Dermatol. 2002;138(3):400–3.CrossRefPubMedGoogle Scholar
  26. 26.
    Galaria NA, Junkins-Hopkins JM, Kligman D, James WD. Neutrophilic dermatosis of the dorsal hands: pustular vasculitis revisited. J Am Acad Dermatol. 2000;43(5 Pt 1):870–4.CrossRefPubMedGoogle Scholar
  27. 27.
    Rockers KM, Fielder LM. Neutrophilic dermatosis of the dorsal hands in a patient treated with chemotherapy for acute myelogenous leukemia. Cutis. 2009;83(1):37–9.PubMedGoogle Scholar
  28. 28.
    Osio A, Battistella M, Feugeas JP, et al. Myelodysplasia cutis versus leukemia cutis. J Investig Dermatol. 2015;135(9):2321–4.CrossRefPubMedGoogle Scholar
  29. 29.
    Karamlou K, Gorn AH. Refractory Sweet syndrome with autoimmune organizing pneumonia treated with monoclonal antibodies to tumor necrosis factor. J Clin Rheumatol. 2004;10(6):331–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Browning CE, Dixon JE, Malone JC, Callen JP. Thalidomide in the treatment of recalcitrant Sweet’s syndrome associated with myelodysplasia. J Am Acad Dermatol. 2005;53(2 Suppl 1):S135–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Chaulagain CP, Miller KB. Lenalidomide as a steroid sparing agent in a myelodysplastic syndrome patient with refractory Sweet syndrome. Int J Blood Res Disord. 2014;1:1.  https://doi.org/10.23937/2469-5696/1410003.CrossRefGoogle Scholar
  32. 32.
    Yamada M, Kuroda H, Yoshida M, et al. Successful treatment of an essential thrombocythemia patient complicated by Sweet’s syndrome with combination of chemotherapy and lenalidomide. Rinsho Ketsueki. 2014;55:440–4.PubMedGoogle Scholar
  33. 33.
    Thieu KP, Rosenbach M, Xu X, Kist JM. Neutrophilic dermatosis complicating lenalidomide therapy. J Am Acad Dermatol. 2009;61(4):709–10.CrossRefPubMedGoogle Scholar
  34. 34.
    Tageja N, Giorgadze T, Zonder J. Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia. Intern Med J. 2011;41(3):286–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Hoverson AR, Davis MD, Weenig RH, Wolanskyj AP. Neutrophilic dermatosis (Sweet syndrome) of the hands associated with lenalidomide. Arch Dermatol. 2006;142(8):1070–1.CrossRefPubMedGoogle Scholar
  36. 36.
    Martinelli S, Rigolin GM, Leo G, et al. Complete remission of Sweet’s syndrome after azacytidine treatment for concomitant myelodysplastic syndrome. Int J Hematol. 2014;99(5):663–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Kulasekararaj AG, Kordasti S, Basu T, et al. Chronic relapsing remitting Sweet syndrome—a harbinger of myelodysplastic syndrome. Br J Haematol. 2015;170(5):649–56.CrossRefPubMedGoogle Scholar
  38. 38.
    Li AW, Yin ES, Stahl M, et al. The skin as a window to the blood: cutaneous manifestations of myeloid malignancies. Blood Rev. 2017;31(6):370–88.CrossRefPubMedGoogle Scholar
  39. 39.
    Avivi I, Rosenbaum H, Levy Y, et al. Myelodysplastic syndrome and associated skin lesions: a review of the literature. Leuk Res. 1999;23(4):323–30.CrossRefPubMedGoogle Scholar
  40. 40.
    Lee SJ, Park JK, Lee EY, et al. Certain autoimmune manifestations are associated with distinctive karyotypes and outcomes in patients with myelodysplastic syndrome: retrospective cohort study. Medicine (Baltimore). 2016;95(13):e3091.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Farah C, Bulai Livideanu C, Jegu J, et al. Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome. J Eur Acad Dermatol Venereol. 2010;24(10):1171–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum. JAMA Dermatol. 2018;154(4):461–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Arhonowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191–211.CrossRefGoogle Scholar
  44. 44.
    Ashchyan HJ, Butler DC, Nelson CA, et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol. 2018;154(4):409–13.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Duguid CM, O’Loughlin S, Otridge B, et al. Paraneoplastic pyoderma gangrenosum. Australas J Dermatol. 1993;34(1):17–22.CrossRefPubMedGoogle Scholar
  46. 46.
    Inoue S, Furuta J, Fujisawa Y, et al. Pyoderma gangrenosum and underlying diseases in Japanese patients: a regional long-term study. J Dermatol. 2017;44(11):1281–4.CrossRefPubMedGoogle Scholar
  47. 47.
    Fox LP. Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia. Leuk Lymphoma. 2006;47(1):147–50.CrossRefPubMedGoogle Scholar
  48. 48.
    Prat L, Bouaziz JD, Wallach D, et al. Neutrophilic dermatoses as systemic diseases. Clin Dermatol. 2014;32(3):376–88.CrossRefPubMedGoogle Scholar
  49. 49.
    Haga N, Iwata H, Yamaguchi Y, et al. Mucocutaneous pyoderma gangrenosum due to trisomy 8 neutrophilic infiltrates in a patient with myelodysplastic syndrome. Br J Dermatol. 2016;174(1):239–41.CrossRefPubMedGoogle Scholar
  50. 50.
    Mekinian A, Grignano E, Braun T, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016;55(2):291–300.CrossRefPubMedGoogle Scholar
  51. 51.
    Malkan UY, Gunes G, Eliacik E, et al. Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case. Int Med Case Rep J. 2016;2016(9):61–4.CrossRefGoogle Scholar
  52. 52.
    Koca E, Duman AE, Cetiner D, et al. Successful treatment of myelodysplastic syndrome-induced pyoderma gangrenosum. Neth J Med. 2006;64(11):422–4.PubMedGoogle Scholar
  53. 53.
    Koester G, Tarnower A, Levisohn D, et al. Bullous pyoderma gangrenosum. J Am Acad Dermatol. 1993;29:875–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Rousset L, De Masson A, Begon E, et al. Tumor necrosis factor-alpha inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: a multicenter retrospective study. J Am Acad Dermatol. 2018.  https://doi.org/10.1016/j.jaad.2018.10.006 (Epub ahead of print).CrossRefPubMedGoogle Scholar
  55. 55.
    Yasukawa K, Kato N, Aikawa K, et al. Neutrophilic eccrine hidradenitis with sclerodermoid change heralding the relapse of acute myelogenous leukemia: is this a paraneoplastic phenomenon? Dermatology. 2007;215(3):261–4.CrossRefPubMedGoogle Scholar
  56. 56.
    Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses. Part I. Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet’s disease. J Am Acad Dermatol. 2018.  https://doi.org/10.1016/j.jaad.2017.11.064.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Bachmeyer C, Aractingi S. Neutrophilic eccrine hidradenitis. Clin Dermatol. 2000;18(3):319–30.CrossRefPubMedGoogle Scholar
  58. 58.
    Gomez Vazquez M, Peteiro C, Toribio J. Neutrophilic eccrine hidradenitis heralding the onset of chronic myelogenous leukaemia. J Eur Acad Dermatol Venereol. 2003;17(3):328–30.CrossRefPubMedGoogle Scholar
  59. 59.
    Yiannias JA, El-Azhary RA, Gibson LE. Erythema elevatum diutinum: a clinical and histopathologic study of 13 patients. J Am Acad Dermatol. 1992;26(1):38–44.CrossRefPubMedGoogle Scholar
  60. 60.
    Aractingi S, Bachmeyer C, Dombret H, et al. Simultaneous occurrence of two rare cutaneous markers of poor prognosis in myelodysplastic syndrome: erythema elevatum diutinum and specific lesions. Br J Dermatol. 1994;131(1):112–7.CrossRefPubMedGoogle Scholar
  61. 61.
    Montanari M, Gemelli C, Tenedini E, et al. Correlation between differentiation plasticity and mRNA expression profiling of CD34+-derived CD14− and CD14+ human normal myeloid precursors. Cell Death Differ. 2005;12(12):1588–600.CrossRefPubMedGoogle Scholar
  62. 62.
    Collins SJ. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood. 1987;70(5):1233–44.PubMedGoogle Scholar
  63. 63.
    Brackman D, Lund-Johansen F, Aarskog D. Expression of cell surface antigens during the differentiation of HL-60 cells induced by 1,25-dihydroxyvitamin D3, retinoic acid and DMSO. Leuk Res. 1995;19(1):57–64.CrossRefPubMedGoogle Scholar
  64. 64.
    Song JH, Kim JM, Kim SH, et al. Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003;73(13):1705–19.CrossRefPubMedGoogle Scholar
  65. 65.
    Trayner ID, Bustorff T, Etches AE, et al. Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, alpha1,25-dihydroxyvitamin D3 or 12-O-tetradecanoyl phorbol-13-acetate. Leuk Res. 1998;22(6):537–47.CrossRefPubMedGoogle Scholar
  66. 66.
    White SL, Belov L, Barber N, et al. Immunophenotypic changes induced on human HL60 leukaemia cells by 1alpha,25-dihydroxyvitamin D3 and 12-O-tetra- decanoyl phorbol-13-acetate. Leuk Res. 2005;29(10):1141–51.CrossRefPubMedGoogle Scholar
  67. 67.
    Clark CS, Konyer JE, Meckling KA. 1alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression. Exp Cell Res. 2004;294(1):301–11.CrossRefPubMedGoogle Scholar
  68. 68.
    Bastie JN, Balitrand N, Guillemot I, et al. Cooperative action of 1alpha,25-dihydroxyvitamin D3 and retinoic acid in NB4 acute promyelocytic leukemia cell differentiation is transcriptionally controlled. Exp Cell Res. 2005;310(2):319–30.CrossRefPubMedGoogle Scholar
  69. 69.
    Dodd RC, Cohen MS, Newman SL, et al. Vitamin D metabolites change the phenotype of monoblastic U937 cells. Proc Nat Acad Sci USA. 1983;80(24):7538–41.CrossRefPubMedGoogle Scholar
  70. 70.
    Harris P, Ralph P. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leukoc Biol. 1985;37(4):407–22.CrossRefPubMedGoogle Scholar
  71. 71.
    Rasaiyaah J, Yong K, Katz DR, et al. Dendritic cells and myeloid leukaemias: plasticity and commitment in cell differentiation. Br J Haematol. 2007;138(3):281–90.CrossRefPubMedGoogle Scholar
  72. 72.
    Van Loon K, Gill RM, McMahon P, et al. 20q–clonality in a case of oral Sweet syndrome and myelodysplasia. Am J Clin Pathol. 2012;137(2):310–5.CrossRefPubMedGoogle Scholar
  73. 73.
    Sujobert P, Cuccuini W, Vignon-Pennamen D, et al. Evidence of differentiation in myeloid malignancies associated neutrophilic dermatosis: a fluorescent in situ hybridization study of 14 patients. J Investig Dermatol. 2013;133(4):1111–4.CrossRefPubMedGoogle Scholar
  74. 74.
    Fathi AT, Le L, Hasserjian R, et al. FLT3 inhibitor-induced neutrophilic dermatosis. Blood. 2013;122(2):239–42.CrossRefPubMedGoogle Scholar
  75. 75.
    Magro CM, Kiani B, Li J, Crowson AN. Clonality in the setting of Sweet’s syndrome and pyoderma gangrenosum is not limited to underlying myeloproliferative disease. J Cutan Pathol. 2007;34(7):526–34.CrossRefPubMedGoogle Scholar
  76. 76.
    Mo W, Wang X, Wang Y, et al. Clonal neutrophil infiltrates in concurrent Sweet’s syndrome and acute myeloid leukemia: a case report and literature review. Cancer Genet. 2018;226–227:11–6.CrossRefPubMedGoogle Scholar
  77. 77.
    Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417–26.CrossRefPubMedGoogle Scholar
  78. 78.
    Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7(2):99–109.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178(1):48–56.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Marzano A, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form PASH. Br J Dermatol. 2017;176(6):1588–98.CrossRefPubMedGoogle Scholar
  81. 81.
    Giasuddin ASM, El-Orfi AH, Ziu MM, et al. Sweet’s syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol. 1998;39:940–3.CrossRefPubMedGoogle Scholar
  82. 82.
    Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood. 2012;119(13):2991–3002.CrossRefPubMedGoogle Scholar
  83. 83.
    Sanchez-Correa B, Bergua JM, Campos C, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013;61(3):885–91.CrossRefPubMedGoogle Scholar
  84. 84.
    Basiorka AA, McGraw KL, Eksioglu EA, et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016;128(25):2960–75.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Mundle SD, Venugopal P, Cartlidge JD, et al. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 1996;88(7):2640–7.PubMedGoogle Scholar
  86. 86.
    Miyoshi T, Yamashita K, Ohno T, et al. Familial Mediterranean fever gene as a possible modifier of Sweet syndrome with chronic myelogenous leukemia. Acta Haematol. 2008;120(1):57–62.CrossRefPubMedGoogle Scholar
  87. 87.
    Jo T, Horio K, Migita K. Sweet’s syndrome in patients with MDS and MEFV mutations. N Engl J Med. 2015;372(7):686–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Clémence Lepelletier
    • 1
    • 2
    Email author
  • Jean-David Bouaziz
    • 1
    • 2
  • Michel Rybojad
    • 1
  • Martine Bagot
    • 1
    • 2
  • Sophie Georgin-Lavialle
    • 3
    • 4
  • Marie-Dominique Vignon-Pennamen
    • 5
  1. 1.Assistance Publique-Hôpitaux de Paris, Département de DermatologieHôpital Saint-LouisParisFrance
  2. 2.Université Paris-Diderot, Sorbonne Paris CitéParisFrance
  3. 3.Assistance Publique-Hôpitaux de Paris, Service de Médecine interneHôpital TenonParisFrance
  4. 4.Université Pierre et Marie Curie, Sorbonne Paris CitéParisFrance
  5. 5.Assistance Publique-Hôpitaux de Paris, Département de PathologieHôpital Saint-LouisParisFrance

Personalised recommendations